It is indicated alone or in combination with warfarin to prevent and treat blood clots in the leg. It is a low molecular weight heparin. Enoxaparin is indicated for preventing and treating blood clots ...
To date, the optimal dosing strategy for VTE prophylaxis in critically ill, morbidly obese patients has not been determined. [20] These patients have generally been excluded from participation in ...
June 14, 2010 (Barcelona, Spain) — Major venous thromboembolism (VTE) and VTE-related mortality occurred in 2.2% of patients receiving oral dabigatran and in 4.2% of patients receiving subcutaneous ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — Treatment with 30 days of low-dose apixaban was no more effective than a shorter course of enoxaparin ...
Anticoagulant efficacy to prevent VTE after hip and knee arthroplasty Fondaparinux and rivaroxaban were associated with increased risk of major bleeding in patients who underwent total hip or knee ...
The Department of Pharmaceuticals (DoP) has rejected a review application of Sanofi India, part of the leading multinational pharma major Sanofi, and upheld the decision of National Pharmaceutical ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...
It is indicated alone or in combination with warfarin to prevent and treat blood clots in the leg. It is a low molecular weight heparin. Enoxaparin is indicated for preventing and treating blood clots ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback